<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00480792</url>
  </required_header>
  <id_info>
    <org_study_id>2006-003940-50</org_study_id>
    <secondary_id>ANRS HB 03 VIHVAC-B</secondary_id>
    <nct_id>NCT00480792</nct_id>
  </id_info>
  <brief_title>Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients</brief_title>
  <acronym>VIHVAC-B</acronym>
  <official_title>Open-label, Randomized, and Multicentric Phase III Clinical Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV-1-infected Patients With CD4-positive T-lymphocytes Counts Above 200 permm3 ANRS HB 03 VIHVAC-B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MCM Vaccines B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In HIV infected patients, individuals exposed to the virus of Hepatitis B are more
      susceptible to develop a chronic and severe liver disease with a major risk of cirrhosis and
      liver cancer.

      However, the existing protocol of vaccination against Hepatitis B is less efficient in
      HIV-infected patients than in non HIV-infected-patients, and, in case of response, its
      longevity has to be followed up carefully. This study compares the efficacy of the standard
      protocol vaccination with GenHevac-B and 2 other protocols, a double-dose of GenHevac-B and a
      set of intradermal injections of Genhevac-B, in HIV-infected patients with lymphocytes T CD4
      level above 200 permm3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of 3 vaccination strategy against Hepatitis B in patients with HIV infection T CD4
      above 200 per mm3

      Intervention:

        1. Arm A: GenHevac-B 20 microgramme Intramuscular use at M0, M1, M6

        2. Arm B: GenHevac-B 40 microgramme Intramuscular use at M0, M1, M2, M6

        3. Arm C: GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV-infected patients who seroconvert in the first two months after the last vaccination. Seroconversion is defined as antibodies AbHBs titers equal or above 10 mUI per ml.</measure>
    <time_frame>two months after the last injection;week 28, month 18, month 30 and month 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>According to the vaccine administration (IM or ID) comparison of AbHBs titers,permanence of the humoral response,intensity of clinical and biological events and predicting factors related to seroconversion</measure>
    <time_frame>two months after the last injection; week 28, month 18, month 30 and month 42</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">437</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GenHevac-B 20 microgramme Intramuscular use at M0, M1, M6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GenHevac-B 40 microgramme Intramuscular use at M0, M1, M2, M6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GenHevac B Pasteur</intervention_name>
    <description>Intra-muscular injection 20 microgramme Intramuscular use at M0, M1, M6</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Sanofi Pasteur MSD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GenHevac B Pasteur</intervention_name>
    <description>Intra-muscular injection 40 microgramme intramuscular use at M0, M1,M2, M6</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Sanofi Pasteur MSD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GenHevac B Pasteur</intervention_name>
    <description>GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Sanofi Pasteur MSD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age Eligible for Study: 18 years - NA, Genders Eligible for Study: Both

        Criteria

        Inclusion criteria:

          -  HIV infection

          -  T CD4 count cell level above 200 per mm3

          -  Serology Hepatitis B negative (AgHBs, AbHBs and AbHBc negative)

          -  unchanged ARV for the last 3 months for patients who are receiving ARV at the
             screening visit

          -  Undetectable for the last 6 months with ARV for any patient with T CD4 level below 350
             per mm3

          -  Pregnancy test negative at the screening and inclusion visits

        Exclusion Criteria:

          -  Any injection of the vaccine against Hepatitis B in the medical history

          -  Acute cytolysis in the last 3 months with transaminases equal or above 5 times the
             upper normal range for HIV-HCV coinfected patients, or transaminases equal or above 2
             times the upper normal for non coinfected patients

          -  Any vaccine received one month before the inclusion

          -  History of intolerance to any component of GenHevac-B

          -  Evolutive opportunistic infection treated the month before the screening visit

          -  Severe and acute pyretic infection or unexplained fever the week before inclusion

          -  Evolutive hemopathy or solid-organ cancer

          -  Prothrombin factor equal or below 50 percent and/or platelets equal or below 50 000
             per mm3

          -  Immunosuppressive treatment or general corticotherapy (equal or above 0,5 mg per kg
             per day during above 7 days) in the last 6 months before the screening visit

          -  Previous Immunomodulating treatment (interferon, interleukin-2,etc) or plan in the
             next 6 months

          -  Splenectomy

          -  Decompensated cirrhosis (Child Pugh B or C)

          -  Kidney deficient function (creatinine clearance below 50 ml per mn)

          -  Other immunocompromised condition not related to HIV infection (solid-organ
             transplantation, chemotherapy in the last 6 months)

          -  Any participation to another clinical trial plan until Week 28
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Odile Launay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIC de vaccinologie Cochin-Pasteur 27, rue du Fb Saint Jacques 75014 Paris Fr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabrice Carrat, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Inserm U707 27, rue de Chaligny 75571 Paris cedex 12 Fr</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Cochin CIC de vaccinologie</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2007</study_first_submitted>
  <study_first_submitted_qc>May 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2007</study_first_posted>
  <last_update_submitted>July 22, 2013</last_update_submitted>
  <last_update_submitted_qc>July 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B vaccination</keyword>
  <keyword>GenHevac-B Pasteur</keyword>
  <keyword>HIV Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

